1. European Medicines Agency. Reflection paper on risk based quality management in clinical trials. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500110059.pdf. Published August 2011. Accessed October 25, 2013.
2. US Department of Health and Human Services, Food and Drug Administration. Draft guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf. Published August 2011. Accessed October 25, 2013.
3. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: oversight of clinical investigations: a risk-based approach to monitoring. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM269919.pdf. Published August 2013. Accessed October 28, 2013.
4. Tantsyura V, Grimes I, Mitchel J, et al. Risk-based source data verification approaches: pros and cons. Drug Information Journal. 2010;44:745–756.
5. Nielsen E, Huder D, Deng C. A data-driven approach to risk-based source data verification. Therapeutic Innovation & Regulatory Science [published online July 22, 2013].